Overview | Identification | Law Enforcement | Disease | Research | Resources
What is DNA, how it can be used
Genetic information about any organism is contained in the organism?s DNA (deoxyribonucleic acid) molecules. DNA is contained in all of the organism?s cells except mature red blood cells. Every cell has two pairs of chromosomes, composed of DNA, except gamete cells (sperm and egg), which have only one set. DNA provides exact instructions for the creation and functioning of the organism. DNA molecules of all organisms contain the same basic physical and chemical components, arranged in different sequences. The genome is an organism?s complete set of DNA.
The current estimate is that humans have between 32,000 and 35,000 genes. About 99.9 percent of the genome is the same in all humans. The arrangement of the remaining components is unique to most individuals. Only identical twins (or triplets, etc.) have identical DNA. Variations in DNA influence how individuals respond to disease, environmental factors such as bacteria, viruses, toxins, chemicals, and to drugs and other therapies. The interaction between genes and environmental factors is not well understood at this time and is the subject of intensive research.
Any properly stored tissue sample can be the source of DNA. ?Handbook of Human Tissue Sources?, published by RAND, estimated that in 1999 there were more than 307 million tissue specimens stored in the United States, and that the number was growing by 20 million per year. These specimens are collected and stored for research, medical treatment, law enforcement, military indentification, blood and tissue banking, fertility treatments and, increasingly, commercial purposes. However, not all tissue collections can be classified as DNA databanks. DNA databanks are composed of a set of tissue specimens, digital DNA profiles, stored in a computer database, and some form of linking between each specimen and the DNA profile derived from it. DNA databanks used in medical and research applications also include links to medical records and family history of individuals whose DNA is stored. Blood and tissue specimens can be preserved indefinitely, and DNA from these specimens can be tested multiple times.
Genetic data poses significant privacy issues because it can serve as an identifier and can also convey sensitive personal information about the individual and his or her family. As genetic science develops, genetic information provides a growing amount of information about diseases, traits, and predispositions. At the same time, smaller and smaller tissue samples are required for testing. In some cases tests can be performed with as little as the root of a single hair or saliva left on a glass from which an individual drank. The ability to derive more information from less and less material creates increasing challenges to privacy because it permits analysis of tiny traces that all humans leave behind unconsciously, such as cells left on computer keys or saliva left on a drinking glass.
The ability of genetic information to provide both identification and sensitive information related to health and other predisposition has led to a lively debate about appropriate privacy protections. Proponents of ?genetic exceptionalism? claim that genetic information deserves explicit and stricter protection under the law. They base their argument on the special qualities of genetic material:
Opponents of ?genetic exceptionalism? take the position that genetic information is much like other personal information and should be protected in the same way. They point to the fact that ?genetic information? is difficult to define because it includes information like family medical history, which has been collected and used by doctors long before the sequencing of the genome. Therefore, they emphasize the importance of context in which genetic information is obtained and used. For example, if genetic information is obtained as part of health care research or treatment, it should be subject to the same privacy and anti-discrimination protections as all other health information.
At present there is no specific protection for DNA information at the federal
level in the United States, although several existing laws may provide protection
under specific circumstances. For example, protection of medical information
under the Privacy Rule of the Health Insurance Portability and Accountability
Act (HIPAA) provides protection for genetic information that falls within
the HIPAA definition of ?protected health information.? The law that would
most likely offer protection against genetically based employment discrimination
is the Americans With Disabilities Act, which has been interpreted by the
Equal Employment Opportunities Commission to include people with genetic
predisposition. The Privacy Act of 1974 protects genetic information in the
same way as all other personal information that falls under the Act?s protection.
Some states have passed
legislation that protects DNA information either as a component of health
information or separately. These state laws are essentially anti-discrimination
Use of DNA for identification
The use of DNA in identification is growing. DNA ?fingerprinting? is a process in which a laboratory creates a profile of specific agreed-upon segments (?loci?) of the DNA molecule. In order to identify a particular individual, the laboratory compares the profile produced from a sample of unknown DNA with the profile produced from a sample known to belong to an identified individual. The laboratory then calculates a statistical probability that a match could take place purely by chance. The more sections match within the two samples, the higher the probability that the DNA belongs to the same individual.
In the United States, the standard for forensic identification requires a comparison of 13 DNA segments. Reliable identification requires that samples be handled carefully to prevent contamination, that a sufficient number of segments be compared, and that researchers set an appropriately high threshold for acceptable probability of a chance match. There have been cases and near-misses of mistaken DNA identification when one or more of these conditions were violated. For example, MSNBC reported that an identification mistake was avoided when the medical examiner insisted on a 99.99 percent certainty of non-random match for the remains of a firefighter who died in the aftermath of the attack on the World Trade Center on September 11, 2001. A sample appeared to match one of the firefighters with 90 percent probability, but additional work showed that at the 99.99 percent level there was a closer match with a different firefighter.
Although DNA identification is generally considered reliable if properly done, there are some people for whom DNA identification could be problematic because of events that took place in the womb during fetal development. As reported in the journal Nature, some people?s cells include DNA of two people. For example, in rare cases fraternal twins may exchange cells before birth and retain those cells, with their twin?s DNA, as adults. Other individuals have different DNA in different tissues of their bodies. The extent of this phenomenon is not known at this time and there has been little discussion of its implications for common uses of genetic identification.
DNA identification has been used in criminal cases, both to convict and
to exonerate, in location of missing persons and war dead, in determining
paternity and tracing genealogy. It has been reported that the next generation
of national identity card in China will carry an 18-digit code representing
a citizen?s genetic code. Below we address various uses of DNA identification
and the privacy issues related to these uses.
Law enforcement agencies around the world are increasingly relying on DNA evidence. Although DNA evidence alone can seldom be used to prove that an individual committed a crime, it can be used to place the individual at the crime scene if the scene contains biological evidence. When a DNA profile is derived from evidence at the crime scene, law enforcement officials can search forensic DNA databases for a matching DNA profile to determine whether the evidence came from an individual who committed a prior offence. They can also request DNA samples from suspects or, in some countries, conduct ?DNA sweeps? of large numbers of people to find an individual whose DNA matches evidence found at the crime scene. In some cases, when the police have a suspect and know of locations where that individual?s tissue samples may be stored, a search warrant may be used to obtain the sample for analysis. The high confidence placed in DNA matches makes it particularly important that biological evidence be handled carefully to avoid contamination and that other evidence be available to link the individual to the crime. DNA evidence has been challenged in courts of several countries because of improper handling during evidence collection or testing.
According to the 2002 global survey by Interpol, 77 of its 179 member countries perform DNA analysis and 41 member countries have forensic DNA databanks, which include both physical samples and databases of DNA profiles. The percentage of members having DNA databanks is predicted to double in the next few years. Interpol is in negotiations to create protocols for searching and sharing DNA profiles across borders as part of its larger initiative on digital communications between law enforcement authorities.
The rules for inclusion in forensic DNA databanks and the rules that govern access to data, physical specimen retention, and privacy protections vary from country to country. In countries that operate under federal systems, such as US and Australia, rules for forensic DNA databanks can vary from jurisdiction to jurisdiction. The United Kingdom has the largest forensic DNA databank, which holds over 2.5 million samples of those who have been charged with one of a list of offenses and, since April 4, 2004, those who have been arrested but not charged.
US law enforcement agencies use databases of DNA profiles, created by the states and linked through the FBI?s Combined DNA Index System (CODIS). These profiles contain the analysis of 13 segments of non-coding DNA, i.e., DNA that does not contain information about predispositions or other characteristics, but varies from individual to individual. The CODIS system, authorized by Congress in 1994, allows law enforcement officials to exchange and compare DNA profiles at the local, state and national levels. As of April 2004, over 1.8 million profiles were accessible through CODIS. The samples on which DNA profiles are based, usually blood or saliva, are kept at forensic laboratories around the country. Samples are generally maintained for a long time in order to permit re-testing if DNA profile evidence is challenged or as technology improves.
States in the US have different legislative requirements for inclusion in DNA databanks. All 50 states require sex offenders to provide DNA samples. In addition, some states require DNA samples from some or all felons, and many states include juveniles in their databanks. Samples of convicted offenders, whose profiles are submitted to the CODIS database, are retained indefinitely. State laws vary about the length of time other samples are retained. In at least one case, an individual who had not been convicted is suing the state to demand the return of his DNA sample. Federal and state law enforcement authorities have urged their legislatures to expand the scope of DNA databases.
Judges in the United States have issued warrants based solely on DNA identification. Indictments and convictions on the basis of DNA evidence alone have also occurred. In August 2003, New York City announced that under the John Doe Indictment Project prosecutors will attempt to link sex crimes to specific DNA profiles and then indict individuals with those DNA profiles before the individuals are identified and named. This is done in order to bring indictment before the statute of limitations expires.
DNA identification is also used to exonerate previously convicted individuals. As of September 2003, more than 130 people have been cleared of crimes through the use of DNA testing. In many cases those who were cleared had served many years in prison and some have spent years on death row. One of the best-known efforts to exonerate individuals through DNA testing is the Innocence Project at the Cardozo School of Law, Yeshiva University. Founded in 1992 by Professor Barry Scheck, the clinical law program provides legal assistance to persons challenging their convictions based on DNA evidence. Similar Innocence Project programs have also started at the University of Wisconsin Law School, the University of Washington School of Law and the Santa Clara University of Law. Several states have passed laws that regulate post-conviction DNA testing.
DNA can also be used to identify remains or biological traces (e.g., blood stains or hair) of missing persons. This is done by matching the DNA material found in the remains or trace with the DNA collected earlier from the presumed missing person or with the DNA of that person?s relatives. Some hospitals and police departments have started offering DNA kits to parents, instructing parents to collect DNA samples from their children, label the samples with the child?s name, Social Security Number and other personal information, and then store the samples in their home freezer. Police would request use of the sample if a child were missing.
Use of DNA in law-enforcement activities is a subject of debate in the United States and other countries. Civil rights, including privacy rights, are at the heart of the debate.
Since the early 1990s, all personnel serving in the United States Armed Forces have been required to submit tissue samples to allow later DNA identification. The samples are stored at the Armed Forces Repository of Specimen Samples for the Identification of Remains. As of 2003, the United States military's DNA depository contains 3.8 million samples, including samples from active duty and reserve personnel. Civilian Department of Defense (DOD) employees and contractor personnel who accompany US forces on deployment may have their specimens included in the DOD DNA bank. DNA analysis of the specimens is not performed on demand. Retrieval and analysis is performed only when there is a requirement to identify human remains. Individuals have the right to request that their samples be destroyed when they conclude their relationship with the DOD (active duty, reserve duty and any other service).
The military?s DNA collection program has had its opponents. Two members
of the United States Marine Corps were ordered to give DNA samples before
being deployed to the Pacific in January 1995. They refused to do so and
were charged with the violation of an order from a superior commissioned
officer. The military court martial dismissed the charges, holding that the
regulations underlying the DNA Repository program were not punitive and thus
no disciplinary action could be taken for refusal to provide specimens. The
two Marines sued the government in federal court, charging that the DNA collection
program violates the Fourth Amendment protection against unreasonable searches
and seizures. The district court found the DNA collection requirement to
be valid. The court of appeals declared the case to be moot because by the
time of the appeal the two Marines had been granted honorable discharges
without ever having given samples of their DNA. Since that time two other
members of the military have refused to give their DNA samples. One was sentenced
by a court martial to 14 days hard labor and a two-grade reduction in rank.
Another temporarily lost his rank and 40 percent of his pay, and was reassigned.
He was later able to claim a narrow exception on religious grounds and was
Paternity testing, fidelity confirmation and other uses of DNA identification
In the past few years there has been an emergence of DNA testing services and repositories created and controlled by the private sector. Companies are promising a variety of services, including individually tailored cosmetics, paternity testing, spousal fidelity confirmation, and genetic ancestry tracing. Some companies store samples for people in high-risk occupations, such as policemen and firemen, so that a loved one may have them identified after death, if needed.
Companies that collect and store genetic information promise confidentiality to their depositors. However, companies? ability to change their privacy policies at any time raise significant concerns that genetic data can be misused, sold or stolen. Many of these companies use academic laboratories for genetic testing and abide by the same confidentiality standards that are mandated for those laboratories, but the companies themselves are not subject to oversight.
Because of the ubiquity of tissue samples from which genetic samples have been derived, there has been significant concern that samples can be taken and tested without individual knowledge or consent. Newspapers have published accounts of attempts by ?genetic trophy hunters? to obtain tissue samples of famous people, such as Prince Harry of Britain. There have also been reports of surreptitious DNA testing in cases of disputed parentage or custody.
Using DNA for identification in uncontrolled circumstances raises complex issues and trade-offs that have not been examined and actively debated in the United States.
Use of DNA for detection and treatment of disease
Genetics holds out the promise for more personalized medicine. This promise is expressed in two ways. First, there is hope that links between genes and disease will allow physicians to assess the risk of illness more accurately and to provide better preventive and treatment alternatives. Second, understanding links between genes and medication response may result in more accurate prescribing, particularly in cases where more than one drug exists for the treatment of a condition. Pharmacogenetics, or the study of links between a genetic profile and reactions to specific medications, is an important field of genetic research.
Links between genes and disease are not simple. Both genetic and environmental factors play a role in the development of disease. Some diseases are a result of a variation in a single gene. Single-gene disorders include cystic fibrosis, sickle cell anemia, Huntington?s disease, and hereditary hemochromatosis. Multifactorial or complex disorders are a result of a combination of mutations in two or more genes and environmental factors such as diet, lifestyle or exposure to specific chemicals or other environmental factors. These multifactorial disorders include heart disease, high blood pressure, Alzheimer?s disease, arthritis, diabetes, cancer, and obesity. Some genetic disorders, such as Down syndrome, are caused by abnormalities in gene-carrying cell structures such as chromosomes or mitochondria. Some genetic mutations are not present at conception but acquired later in life. According to the Human Genome Project Web site on genetic testing, over 900 genetic tests are currently available to determine whether an individual has one of the genes linked to a single-gene disorder and the number of tests is rapidly growing.
For multifactorial disorders, the links between genes and disease are not well understood. Generally, it appears that genetic information may provide some indication of vulnerability, but it is not possible to say whether or not a specific individual will develop the disease, when disease might develop, or how severe it will become. For example, the Washington Post reported that in 2003 researchers identified a gene responsible for the development of depression after exposure to stress. People with a variation in that gene are more than twice as likely as people with the normal version of the gene to react to a traumatic event by becoming depressed. Nevertheless, 57 percent of people with the mutated gene never became depressed and 17 percent of people without the mutation developed depression in response to similar crises.
Some genetic mutations that are associated with disorders are also associated with increased chances of survival in some environmental contexts. For example, sickle cell anemia is caused by a mutation in the hemoglobin gene, and is common among individuals from Africa and the Mediterranean area. However, being a carrier for sickle cell anemia gives the individual protection against malaria because carriers have abnormal red blood cells that die soon after being infected with the malaria parasite. Thus, the mutation gives a survival advantage to individuals who live in areas where malaria is endemic.
At present, genetic testing for disease predisposition is only minimally regulated in the United States. Under the Clinical Laboratories Improvement Act, clinical diagnosis may be made only on the basis of a test result from a laboratory that has been certified to conduct a particular genetic test. However, laboratories are permitted to perform genetic tests without certification. A few states have established regulatory guidelines for genetic testing.
In addition to genetic tests available through health care professionals, there has been significant growth of genetic testing kits marketed directly to consumers. Some see the availability of home testing kits as a positive development, allowing individuals to perform genetic tests privately and to make a choice about whether to disclose results to anyone. However, there are questions about the scientific validity of some tests on the market. There are also concerns that in-home tests do not provide genetic counseling for the interpretation of results, as is usually the case with tests offered through the medical community. Without help, individuals may not properly interpret genetic test results or understand their treatment and prevention options because even highly educated individuals are not always skilled at understanding opportunities and risks presented in terms of likelihoods or probabilities.
Growing research on identifying genes related to specific diseases poses several privacy and civil rights issues.
Pre-implantation testing and testing of newborns
Genetic testing can take place at almost any stage of human development. Couples that have babies through in vitro fertilization (IVF) can test embryos before they are implanted in a woman?s uterus. Babies can be tested in the womb by withdrawing small samples of their tissues. For many years newborns have been routinely tested for some diseases, although testing until recently has generally not involved DNA analysis.
Pre-implantation testing of embryos has grown with the increasing use of IVF technology. The DNA of an eight-cell human embryo can be examined for genetic traits and abnormalities, allowing prospective parents to determine which embryos they wish to implant. Physicians involved with IVF see this as a positive development, permitting an increasing number of healthy births. They generally focus on the ability of people who carry a gene for a known disorder to choose an embryo that is free of that disorder. Some opponents of abortion even see pre-implantation testing as a way to make ?choice? about a pregnancy before the pregnancy begins. However, the ability to ?customize? babies causes concerns among ethicists, as they envision a future in which embryos are selected not only to minimize potential illness but to enhance competitive advantage and social status through traits such as height, eye color, musical talent, athletic ability or intelligence. Austria, Germany, Ireland and Switzerland have outlawed pre-implantation genetic testing on ethical grounds. France, Belgium, the Netherlands and United Kingdom have placed restrictions on the use of pre-implantation genetic testing.
Newborns of industrialized countries have been screened for many years to determine whether they have inborn errors of metabolism and some other genetic conditions. The newborn screening cards, generally known as Guthrie cards, contain blood samples and represent a large collection of specimens from which DNA can be derived. In addition, they contain personal information such as the mother?s name and address, hospital of birth, baby?s medical records number, and the name and address of the baby?s doctor. Different laboratories store Guthrie cards under different conditions and for different lengths of time. There is no general agreement about how long the cards should be kept. Some laboratories discard their cards after several weeks or months, when the cards are no longer necessary for quality control and similar purposes. Others keep Guthrie cards for years, enabling them to use the cards to help in investigation of babies? deaths. In the UK, the Human Genetics Commission is working on a report that considers creating and storing genetic profiles of all newborns for future use in individualized medical treatment.
Although some laboratories have been keeping the cards for longer periods, others have discarded cards because of concern that the cards might be misused. There has been at least one case in which law enforcement officials have attempted to gain access to Guthrie cards as a source of DNA. When Guthrie cards were requested from a laboratory in Australia, laboratory officials destroyed the cards rather than provide access because such use of baby DNA was clearly not envisioned by the parents when they agreed to testing. There has been concern in the medical community that unless Guthrie cards are protected from re-use, parents will be reluctant to have their babies tested.
Genetic testing of embryos and newborns raises privacy issues.
DNA and behavior
One of the more controversial areas of genetics research is the linking of genes and behavior. Researchers have made claims that genes influence such traits as alcoholism, homosexuality, thrill seeking, nurturing, and tendencies towards violent criminal behavior. These claims are based on indications that some behaviors are species-specific, can persist from generation to generation, and can change as a result of brain injury or other biological alteration. However, most human behaviors are complex and result from a life-long interaction between the genes and the environment. Certain genes are expressed only after an environmental trigger turns them ?on.? An individual?s environment can also determine the extent to which behavioral predispositions are expressed. A recent review of genetic research by the Nuffield Council on Bioethics in the UK found that very little is known about the links between genes and human behavior.
Behavioral genetics involves several scientific difficulties. First, it is often difficult to define some behavioral traits. Intelligence is an excellent example of this, with many controversies that have arisen over the years. Second, even if a trait can be defined, it is not clear how to measure it or what constitutes the expression of the trait. For example, do people who like to ride roller-coasters engage in the same type or extent of thrill-seeking behavior as people who jump out of airplanes, and how can ?thrill-seeking? be measured? Third, behavioral traits are often culturally defined. An individual who might be considered lazy in a culture that places primary value on work productivity may be considered a workaholic in a culture that values leisure and non-work-related pursuits. Finally, it is extremely difficult to determine the precise extent to which various genetic and environmental factors determine behavior.
Attempts to link genetics and behavior raise privacy and civil rights issues.
Use of DNA for research
Finding connections between genes, lifestyle and disease requires databases that link the physical tissue sample (e.g., blood or saliva) with the DNA analysis of the sample and the medical and personal history of the individual. The links have to be maintained over time, particularly in cases where researchers are looking to track disease development. The need to maintain links between individual identity and highly personal, sensitive information in an easily searchable database creates privacy concerns. These concerns are amplified by the fact that it is not possible at present to envision all the research projects for which the collected genetic information will be useful, so the usual process of obtaining informed consent from participants may not always be meaningful.
Genetic research databases raise the following privacy concerns:
International genetic databases
Because links between genes and diseases or genes and behavior are statistical in nature, it is only possible to determine such links in a scientifically valid manner when a large number (potentially thousands) of people who exhibit a disease or a behavior are compared to a large number of ?controls? who do not exhibit the trait. Statistical validity of the findings is further improved when unrelated variation is minimized by making comparisons on people who have common ancestry. This means that large national genetic databases are a highly desirable resource for genetic research. Several countries are developing such large databases, often in ways that seek to share risks and rewards with private sector companies.
In 1998, the government of Iceland passed the Act on Health Sector Database (HSD), which authorized the creation of a database that includes genetic information about the country?s entire population of 285,000 people. Because the population of Iceland has been relatively stable and isolated for over a thousand years, the database will be used to combine genetic, disease and genealogical data to identify genes linked to specific diseases, the proteins encoded by these genes, and drugs that can be used to treat the diseases.
The database, managed by a private company deCODE Genetics, includes genetic and medical information collected as part of Iceland?s national health system. The government of Iceland has the right to use the database for planning and policy purposes, but deCODE Genetics has an exclusive commercial license that gives it control over the database for 12 years. In exchange for commercial exclusivity, deCODE Genetics is obligated to provide the people of Iceland with free drugs and therapies that are developed as a result of research on the Icelandic population database.
At the start of the project, consent for the participation in the database was assumed to be implicit. The database was created from the available records and the project was initiated. After various groups, including the Iceland Medical Association, raised concerns about compulsory participation and possibly inadequate privacy safeguards, individuals were given the right to have their data excluded from the database by notifying their physicians. It has been reported that by June 2003 more than 20,000 Icelanders (more than 10 percent of the adult population) had opted out of the research plan. The Association of Icelanders for Ethics in Science and Medicine (Mannvernd) was formed to oppose HSD. The first lawsuit to test the validity of the Act was filed in 2001, with hearings still taking place in the beginning of 2003. As of the summer of 2003, deCODE Genetics is still redesigning database structures to improve privacy protection. At the same time, the company is publishing well-regarded research conducted on a separate database in which 80,000 Icelanders have chosen to participate.
The former Soviet state of Estonia is developing a population-wide genetic database. The database is expected to include samples from about one million of Estonia?s 1.4 million people. The database is being developed by the Estonian Genome Project Foundation, created by the government of Estonia within the jurisdiction of the Ministry of Social Affairs. The Foundation owns the database and is responsible for privacy protection of the participants. Research and commercialization of results will be carried out by Egeen International, a commercial company located in California and given the exclusive commercial license to the database. Egeen raised its first round of private financing in November 2002. Profits derived from the commercialization of results are to be shared between investors and the Estonian Genome Project Foundation. The main focus of the Estonian database is pharmaceutical research, starting with research that correlates genetic make-up, lifestyle and environmental factors with response to particular anti-depressant medications.
Unlike the Icelandic database, participation in the Estonian database has been voluntary from the start and based on explicit consent of the individual. Individuals have a right to access their data, can give permission to their physicians to obtain their information, and can request to be notified of any relevant tests or treatments developed from the database. Although there is no organized opposition to the project, concerns have been raised because physicians are being paid about five times their normal hourly rate to recruit patients for participation. This might provide inducement to physicians to present participation in a more favorable light than they would if they were not given heavy incentives.
The United Kingdom is working on assembling a large genetic research database. UK Biobank, a joint venture of the Medical Research Council, the Wellcome Trust and the Department of Health. UK Biobank plans to collect 500,000 samples from men and women, aged 45 to 69. Genetic information will be combined with environmental and lifestyle information in order to study interaction between genetic, environmental and lifestyle factors in disorders such as cancer, heart disease, diabetes and Alzheimer?s disease. UK Biobank plans to start recruiting participants in 2004.
The UK Biobank project has been controversial not only because its high cost is perceived as detracting from other worthwhile projects, but also because of privacy concerns as biotechnology and pharmaceutical companies access the data to create new diagnostics and therapies. UK Biobank?s founders responded to various criticisms by setting up an independent oversight body to monitor how data and results will be used. They have provided assurances that participating companies, insurers and employers will not be able to get individually identifiable information, and that police will be given information only if required by court order.
A large-scale Swedish biobank is managed by UmanGenomics, which was created in 1999 in order to commercialize the large population based Medical Biobank in Ume?. Originally established by a group of scientists, the Biobank contains detailed medical information for the relatively homogenous population of V?sterbotten in Sweden. The Biobank contains DNA, plasma samples, and biochemical and lifestyle data from more than 66,000 individuals and is linked to high quality disease registries. It is regulated under the Swedish Act on Biobanks, which came into force on January 1, 2003.
Several other national databases and large research projects are being carried out.
Canada: G?nome Qu?bec is a not-for-profit organization that is promoting genetic research on Quebec?s population. The funding is provided by the Canadian federal government, the Quebec Ministry of Research, Science and Technology and the private sector.
United States: Several large research projects are under way, including a project at Howard University that will use samples from 25,000 individuals to look for genetic factors in diseases that are disproportionately prevalent in people of African descent.
Law and policy
December 4, 2008